MedTrace Logo

Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC

NCT07399015 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-02-18

No results posted yet for this study

Summary

An expanded access program (EAP) allows doctors to give medicine to seriously ill patients before it is approved by local regulatory agencies.

The goal of this Expanded Access Protocol is to provide access to mifomelatide for eligible cachectic adult patients with advanced, unresectable pancreatic ductal adenocarcinoma (PDAC) who lack satisfactory therapeutic alternatives for their cancer cachexia and are not eligible for current mifomelatide clinical trials.

A participant may receive mifomelatide under this EAP if:

* A licensed doctor submits a request,
* The participant is eligible
* The country allows the EAP

Conditions

  • Pancreatic Ductal Adenocarcinoma (mPDAC)
  • Unresectable Pancreatic Ductal Adenocarcinoma
  • Metastatic PDAC

Interventions

DRUG

mifomelatide

Eligible participants will receive 25 mg mifomelatide daily by subcutaneous (SC) injection for up to 13 weeks.

Sponsors & Collaborators

  • Endevica Bio

    lead INDUSTRY

Principal Investigators

  • Meghan Joly, PhD · Endevica Bio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07399015 on ClinicalTrials.gov